Evaluation of angiogenesis with vascular endothelial growth factor in patients with thalassemia major

Pediatrics International

Volumn 52, Issue 2, 2010, Pages 247-251

  Olgar, Seref ^a   Kara, Aslihan ^a   Hicyilmaz, Hicran ^a   Balta, Nihal ^b   Canatan, Duran ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Antalya State Hospital   (Turkey)

Author keywords

Angiogenesis; Blood transfusion; Erythropoiesis; Splenectomy; Thalassemia major

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIGOXIN; FERRITIN; FOLIC ACID; HEMOGLOBIN; INSULIN; LEVOTHYROXINE SODIUM; LEVOTIRON; UNCLASSIFIED DRUG; VASCULOTROPIN; ZINC; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGE; ANGIOGENESIS; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SPLENECTOMY; THALASSEMIA MAJOR; BETA THALASSEMIA; BLOOD; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77950237503     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2009.02956.x     Document Type: Article

References (50)

1. Tiozzo S, Voskoboynik A, Brown FD, De Tomaso AW. A conserved role of the VEGF pathway in angiogenesis of an ectodermally-derived vasculature. Dev. Biol. 2008 315 : 243 255.
2. Bikfalvi A. Angiogenesis: Molecular mechanisms of activation, promotion and maintenance. J. BUON 2007 12 (Suppl. 1 S59 66.
3. Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. Int. Rev. Exp. Pathol. 1976 16 : 207 248.
4. Sholley MM, Ferguson GP, Seibel HR et al. Mechanisms of Neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. Lab. Invest. 1984 51 : 624 634.
5. Musolino C, Calabro' L, Bellomo G et al. Soluble angiogenic factors: Implications for chronic myeloproliferative disorders. Am. J. Hematol. 2002 69 : 159 163.
6. Ferrera N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999 56 : 794 814.
7. Eichmann A, Corbel C, Nataf V et al. Ligand dependant development of endothelial and hemopoietic lineage from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc. Natl. Acad. Sci. USA 1997 94 : 5141 5146.
8. Déry MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: Regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell Biol. 2005 37 : 535 540.
9. Dunst J, Pigorsch S, Hänsgen G et al. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther. Onkol. 1999 175 : 93 6.
10. Rakusan K, Cicutti N, Kolar F. Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 2001 280 : H1407 14.
11. Harrison L, Blackwell K. Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004 9 (Suppl. 5 31 40.
12. Old JM, Olivieri N F, Thein SL. Diagnosis and management of thalassemia. In : Weatherall J, Clegg JB (eds). The Thalassemia Syndromes, 4th edn. Blackwell Scientific, Oxford, 2001 597 723.
13. Hornig C, Behn T, Bartsch W et al. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J. Immunol. Methods 1999 226 : 169 177.
14. Cotter M, Gulmann C, Jeffers M, Smith OP. Increased bone marrow angiogenesis in children with severe chronic neutropenia treated with granulocyte colony-stimulating factor. J. Pediatr. Hematol. Oncol. 2004 26 : 504 506.
15. Nakayama N, Fang I, Elliott G. Natural killer and B-lymphoid potential in CD34- cells derived from embryonic stem cells differentiated in the presence of vascular endothelial growth factor. Blood 1998 91 : 2283 2295.
16. Kennedy M, Firpo M, Choi K et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 1997 386 : 488 493.
17. Liang D, Chang JR, Chin AJ et al. The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development. Mech. Dev. 2001 108 : 29 43.
18. Giles FJ, Stopeck AT, Silverman LR et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003 102 : 795 801.
19. Padró T, Bieker R, Ruiz S et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002 16 : 1302 1310.
20. Verstovsek S, Estey E, Manshouri T et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br. J. Haematol. 2002 118 : 151 156.
21. Lanzkowsky P. Thalassemias. Manual of Pediatric Hematology and Oncology. Academic Press, San Diego, CA, 2000 181 191.
22. Füreder W, Krauth MT, Sperr WR et al. Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia. Am. J. Pathol. 2006 168 : 123 130.
23. Padró T, Ruiz S, Bieker R et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000 95 : 2637 2644.
24. Gimbrone M, Leapman S, Cotran R, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 1972 136 : 261 276.
25. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 339 : 58 61.
26. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vivo and in vitro. Lab. Invest. 1994 71 : 374 379.
27. Shima DT, Adamis AP, Ferrera N et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol. Med. 1995 1 : 182 193.
28. Koury ST, Koury MJ, Bondurant MC et al. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: Correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 1989 74 : 645 651.
29. Schuster SJ, Wilson JH, Erslev AJ, Caro J. Physiologic regulation and tissue localization of renal erythropoietin messenger RNA. Blood 1987 70 : 316 318.
30. Schuster SJ, Badiavas EV, Costa-Giomi P et al. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure. Blood 1989 73 : 13 16.
31. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 1993 82 : 3610 3615.
32. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 1994 269 : 4355 4359.
33. Sulkowska M, Wincewicz A, Chabowska A et al. To give or not to give recombinant EPO to anemia endangered cancer patients. Prague Med. Rep. 2006 107 : 281 289.
34. Kase S, Osaki M, Jin XH et al. Increased expression of erythropoietin receptor in human pterygial tissues. Int. J. Mol. Med. 2007 20 : 699 702.
35. Efthimiadou A, Pagonopoulou O, Lambropoulou M et al. Erythropoietin enhances angiogenesis in an experimental cyclosporine A-induced nephrotoxicity model in the rat. Clin. Exp. Pharmacol. Physiol. 2007 34 : 866 869.
36. Wiesener MS, Münchenhagen P, Gläser M et al. Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int. J. Cancer 2007 121 : 2434 2442.
37. Hardee ME, Cao Y, Fu P et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007 2 : e549.
38. Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 2005 353 : 782 792.
39. Böcker-Meffert S, Rosenstiel P, Röhl C et al. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest. Ophthalmol. Vis. Sci. 2002 43 : 2021 2026.
40. Alvarez Arroyo MV, Castilla MA, González Pacheco FR et al. Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J. Am. Soc. Nephrol. 1998 9 : 1998 2004.
41. Paritpokee N, Wiwanitkit V, Bhokaisawan N et al. Serum erythropoietin levels in pediatric patients with beta-thalassemia/hemoglobin E. Clin. Lab. 2002 48 : 631 634.
42. Chaisiripoomkere W, Jootar S, Chanjarunee S, Ungkanont A. Serum erythropoietin levels in thalassemia major and intermedia. Southeast Asian J. Trop. Med. Public Health 1999 30 : 786 788.
43. Nişli G, Kavakli K, Aydinok Y et al. Serum erythropoietin levels in patients with beta thalassemia major and intermedia. Pediatr. Hematol. Oncol. 1997 14 : 161 167.
44. Dore F, Bonfigli S, Gaviano E et al. Serum erythropoietin levels in thalassemia intermedia. Ann. Hematol. 1993 67 : 183 186.
45. Patel HB, Nasir FA, Nash GF et al. Enhanced angiogenesis following allogeneic blood transfusion. Clin. Lab. Haematol. 2004 26 : 129 135.
46. Nielsen HJ, Werther K, Mynster T, Brünner N. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 1999 39 : 1078 1083.
47. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1997 1331 : 1 40.
48. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 : 739 761.
49. Yu Y, Wong J, Lovejoy DB et al. Chelators at the cancer coalface: Desferrioxamine to triapine and beyond. Clin. Cancer Res. 2006 12 : 6876 6883.
50. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons : Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987 47 : 5155 5161.